Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Kristin Palmsten · HEALTHPARTNERS INSTITUTE · 2024 · $548,002 — The efficacy of coronavirus disease (COVID-19) vaccines available in the US is up to 95% against symptomatic COVID-19. However, pregnant and lactating individuals were excluded from initial clinical trials. COVID-19 vaccine trials are now underway in pregnant women in their second or third trimester…
Eleftherios Michailidis · EMORY UNIVERSITY · 2024 · $21,207 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
Sharon Aviran · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $164,971 — Natural and synthetic RNAs play key roles in cellular function, biotechnology, and medicine. RNAs fold into intricate structures, which often drive their functions, thus determining RNA structure is fundamental to biology and biotechnology. Computational thermodynamics-based secondary structure mode…
Brian Lim Hoh · UNIVERSITY OF FLORIDA · 2024 · $75,099 — Diffuse Midline Glioma (DMG) is an inoperable pediatric brain tumor with no good treatment options. Our group has developed a novel treatment modality for this disease and others, using mRNA vaccines consisting of tumor derived antigens packed into a unique lipid nanoparticle (NP). They can provide …
FREDERICK R BLATTNER · SCARAB GENOMICS, LLC · 2024 · $842,151 — Abstract E. coli has played a vital role in the production of recombinant proteins and plasmid DNA (pDNA) for therapeutic use since the advent of the biopharmaceutical industry. E. coli remains the workhorse in the production of heterologous proteins and pDNA because of its short doubling time, its …
Somes Kumar Das · AVERY BIO CORPORATION · 2024 · $295,923 — The long-term objective of this research program is to greatly increase the availability of large DNA constructs for biomedical researchers, by providing a new, highly automated, and low-cost way of making long synthetic DNA molecules. Gene-length DNA is routinely used by genetic engineers to delive…
GRACE Yoonheekim GOMBOLAY · EMORY UNIVERSITY · 2024 · $201,398 — PROJECT SUMMARY/ABSTRACT Mounting an effective antibody and cellular immune response to SARS-CoV-2 vaccination is critical for its efficacy to reduce the risk of severe complications and death in COVID-19. Patients with multiple sclerosis (pwMS) are at increased risk for severe COVID-19 and can have…
Xiang-Yang Shawn Wang · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $577,293 — Abstract Melanoma is the most serious type of skin cancer. Although immune checkpoint blockade (ICB) therapy has benefited many melanoma patients, most patients do not respond to current ICB. Vaccines can promote ICB therapeutic efficacy by generating or amplifying tumor-reactive T cells. Convention…
Hamideh Parhiz · UNIVERSITY OF PENNSYLVANIA · 2024 · $718,306 — Project Summary For HIV cure approaches to be widely implemented, they will need to be safe, affordable and highly effective. The development strategies that allow therapeutic agents to be infused into people living with HIV (PLWH) rather than being manufactured ex vivo may represent an important st…
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2024 · $459,647 — Project summary: We and others have demonstrated that antigens derived from infectious viral infections persist in the host for extended periods of time, well beyond the time in which the infection is cleared from the host. Our lab has specifically identified that antigens derived from both vaccinat…
Peter Shen · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $467,787 — PROJECT SUMMARY Poxviruses include family members that are categorized as Class A Priority Pathogens with significant future pandemic potential, while modified forms of other family members are widely used as vaccine vectors and oncolytic therapeutics. Beyond their more direct medical significance, …
Brian D Brown · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $559,205 — Nucleoside modified RNA-based drugs (modRNA) are a powerful new class of medicine. One type of modRNA, RNA vaccines, has been pivotal in immunization to SARS-CoV-2. modRNA is delivered via lipid nanoparticles (LNP), and antigen presented by whichever cells take up and expresses the modRNA. The ident…
Tian Wang · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $671,187 — SUMMARY: The Coronavirus disease 2019 virus (COVID-19) pandemic has made a devastating impact on global public health and economy over the past three years. Despite the success in rapid progress of COVID-19 vaccine development, increasing rates of variants of concern (VOCs) with enhanced viral trans…
Johannes Morstein · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $163,080 — Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to treating cancer, including cancer immunotherapy, cancer nanotherapy (e.g. liposomal doxorubicin or mRNA vaccines), or new types of biologics and small molecules. I prop…
Aaron M. Johnson · UNIVERSITY OF COLORADO DENVER · 2024 · $207,185 — PROJECT SUMMARY Specific long noncoding RNAs (LncRNAs) that are overexpressed in breast cancer aid in diagnosis and promote molecular mechanisms that drive breast cancer progression. Our recent work has identified a breast- cancer associated LncRNA that converts from an oncogene to a tumor suppress…
ANDREW HAYHURST · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $247,500 — ABSTRACT The current coronavirus (CoV) pandemic, seasonal infections by other CoV and other “cold” viruses, plus the need for annual influenza vaccinations exemplify the challenges posed by viral antigenic drift and shift. Targeting landscapes of viral structural proteins displayed on the surfaces …
Keiichiro Kushiro · MUCOMMUNE, LLC · 2024 · $291,458 — Project Summary: Polyethylene glycol (PEG) is routinely used in protein and nanoparticle therapeutics, with dozens of PEGylated drugs approved to date. Although PEG itself is exceptionally safe, patients can form high titers of anti-PEG antibodies (APA) to some PEGylated drugs. This results not onl…
Paul Joshua Hurst · STANFORD UNIVERSITY · 2024 · $76,408 — Project Summary/Abstract The proposed research will improve the understanding of structure-property-function relationships in formulations of charge-altering releasable transporter (CART) gene delivery vectors. These materials demonstrate remarkable efficiency for mRNA transfection with low cytotox…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $409,859 — Project Summary CRISPR/Cas-based gene editing has ushered in a hopeful era that dreams of new therapies for currently untreatable genetic diseases. Because mutated proteins are produced in specific cells, there is a critical need to develop organ- and cell-specific delivery strategies to realize the…
RONALD LEVY · STANFORD UNIVERSITY · 2024 · $525,103 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…